Get the Stockscreener App
9.21
4.86%
-0.47
After Hours:
9.28
0.07
+0.76%
Immunome Inc stock is traded at $9.21, with a volume of 5.21M.
It is down -4.86% in the last 24 hours and down -7.06% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$9.68
Open:
$9.68
24h Volume:
5.21M
Relative Volume:
5.47
Market Cap:
$801.68M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.781
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
-12.45%
1M Performance:
-7.06%
6M Performance:
+0.00%
1Y Performance:
-37.39%
1-Day Range:
$9.19
$10.27
1-Week Range:
$8.665
$10.41
52-Week Range:
$5.1501
$16.73
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.21 | 783.41M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-25 | Initiated | Craig Hallum | Buy |
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Immunome, Inc. $IMNM Shares Acquired by Adage Capital Partners GP L.L.C. - MarketBeat
Using Ichimoku Cloud for Immunome Inc. technicalsMarket Activity Report & Reliable Entry Point Trade Alerts - Newser
How to interpret RSI for Immunome Inc. stockMarket Sentiment Report & Daily Growth Stock Tips - Newser
Visual trend scoring systems applied to Immunome Inc.2025 Market WrapUp & Daily Profit Maximizing Trade Tips - Newser
Should you wait for a breakout in Immunome Inc.July 2025 Summary & Daily Technical Stock Forecast Reports - Newser
Is Immunome Inc. stock reversal real or fakeAnalyst Downgrade & Safe Capital Preservation Plans - Newser
Has Immunome Inc. found a price floorMarket Trend Summary & Reliable Entry Point Trade Alerts - Newser
Will Immunome Inc. continue its uptrendPortfolio Risk Report & Weekly High Potential Stock Alerts - Newser
How to track smart money flows in Immunome Inc.2025 Growth vs Value & Long-Term Growth Plans - Newser
Is Immunome Inc. building a consolidation baseQuarterly Risk Review & Weekly Momentum Stock Picks - Newser
Zimmer Partners LP Takes $673,000 Position in Immunome, Inc. $IMNM - MarketBeat
Using Python tools to backtest Immunome Inc. strategiesEarnings Performance Report & Low Volatility Stock Recommendations - Newser
Heatmap analysis for Immunome Inc. and competitorsPortfolio Profit Report & Daily Chart Pattern Signal Reports - Newser
Granahan Investment Management LLC Acquires 105,032 Shares of Immunome, Inc. $IMNM - MarketBeat
Is Immunome Inc. trending in predictive chart modelsLong Setup & Real-Time Volume Spike Alerts - Newser
Price momentum metrics for Immunome Inc. explainedJuly 2025 Gainers & Precise Buy Zone Identification - Newser
How to forecast Immunome Inc. trends using time seriesWeekly Risk Report & Entry Point Confirmation Signals - Newser
263,841 Shares in Immunome, Inc. $IMNM Purchased by Exome Asset Management LLC - MarketBeat
Best data tools to analyze Immunome Inc. stockEarnings Miss & High Return Trade Opportunity Guides - Newser
37,114 Shares in Immunome, Inc. $IMNM Acquired by Walleye Capital LLC - MarketBeat
using python tools to backtest immunome inc. strategies2025 Biggest Moves & Verified Entry Point Detection - Newser
Using Bollinger Bands to evaluate Immunome Inc.Portfolio Update Report & Precise Buy Zone Identification - Newser
Is a relief rally coming for Immunome Inc. holdersEarnings Overview Report & Low Drawdown Trading Techniques - Newser
What Fibonacci levels say about Immunome Inc. reboundMarket Sentiment Summary & Daily Profit Focused Stock Screening - Newser
Immunome, Inc. $IMNM Shares Bought by EcoR1 Capital LLC - MarketBeat
Immunome, Inc. $IMNM Shares Bought by Corebridge Financial Inc. - Defense World
Will Immunome Inc. price bounce be sustainableM&A Rumor & Safe Swing Trade Setups - Newser
MetLife Investment Management LLC Purchases 6,792 Shares of Immunome, Inc. $IMNM - Defense World
Immunome Inc.’s volatility index tracking explainedWall Street Watch & Low Risk Entry Point Guides - Newser
Immunome Inc. Stock Recovery Path — Analyst BreakdownDip Buying & Verified Entry Point Signals - beatles.ru
Are Bears Losing Grip on Immunome Inc.Quarterly Earnings Summary & Long-Term Safe Investment Plans - beatles.ru
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):